sp should be 5x imho, page-907

Nothing wrong with competition and the purchase of the T-cell platform by BioNTech, as you say, "is good news for the entire imuno oncology bio sector."

There's an interesting statement made by Rebecca Lim, our Director of Scientific Affairs, in the OmniCar presentation, that resonated with me. She says (to the effect and not verbatim) that what differentiates our OmniCar platform from others is its simplicity of manufacture. It's mechanics is readily manufactured whereas others have failed due to their complex nature.